Co-Diagnostics Analyzes Flu Detection Technology, Ensures High Sensitivity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy CODX?
Source: Newsfilter
- Technology Stability: Co-Diagnostics conducted an analysis of its Logix Smart ABC test's Co-Primers® against 3,900 influenza sequences, confirming comparable reactivity to the H3N2 subclade K, which underscores the stability and reliability of its technology since its initial development over five years ago.
- Market Demand Response: CEO Dwight Egan noted an increase in customer inquiries regarding the Logix Smart ABC test's performance against influenza strains, indicating a sustained demand for high-quality PCR testing solutions, thereby enhancing the company's competitive position in the market.
- Clinical Testing Progress: In November 2025, the company initiated clinical performance testing for the Co-Dx PCR Flu A/B, COVID-19, and RSV multiplex test, aimed at supporting a 510(k) submission to the FDA, which will further expand its product line and increase market share.
- Global Health Impact: According to the World Health Organization, seasonal influenza causes 290,000 to 650,000 respiratory fatalities annually, and Co-Diagnostics' technology is poised to enhance detection capabilities to address influenza outbreaks, thereby improving public health safety.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CODX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CODX
Wall Street analysts forecast CODX stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
Low
1.50
Averages
1.50
High
1.50
Current: 0.000
Low
1.50
Averages
1.50
High
1.50
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Co-Diagnostics Strengthens Distributor Network in India with CoSara
- Distributor Network Expansion: CoSara Diagnostics has strengthened its distributor base in India, exceeding 40 distributors, and enhanced market penetration through participation in regional conferences.
- Product Promotion Opportunities: At two recent regional conferences, CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform, attracting new customers and solidifying existing relationships.
- Clinical Study Preparation: CoSara is preparing to assist in clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis test, demonstrating its active involvement in public health initiatives.
- Manufacturing Collaboration: CoSara will participate in the production of the PCR Pro™ instrument and MTB test cups, supporting the
See More
Co-Diagnostics Strengthens Distributor Network in India with CoSara, Expanding to Over 40 Distributors
- Distributor Network Expansion: CoSara Diagnostics is strengthening its distribution network in India by participating in two regional conferences, successfully attracting new customers and expanding its base of over 40 distributors, indicating positive progress in market penetration.
- Product Promotion Opportunities: At the conferences, CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform, aiming to enhance brand visibility and lay the groundwork for future sales, further driving growth in the Indian market.
- Clinical Study Preparation: CoSara is preparing for clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) test, which not only helps enhance product market recognition but also strengthens its influence in public health.
- Manufacturing Collaboration: CoSara will participate in the manufacturing of the PCR Pro™ instrument and MTB test cups, supporting the
See More
Co-Diagnostics Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
- Reverse Stock Split: Co-Diagnostics announced a 1-for-30 reverse stock split effective January 2, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00, thereby mitigating delisting risks.
- Shareholder Approval: The reverse split was approved by shareholders at a special meeting on December 5, 2025, reflecting strong support for corporate governance and future growth, which enhances market confidence.
- Stock Trading Adjustment: Following the reverse split, Co-Diagnostics' stock will continue trading on Nasdaq under the new CUSIP number 189763 204, ensuring a smooth transition for investors into the adjusted trading environment.
- Equity Incentive Impact: The split will affect the number of stock options and warrants outstanding, with a corresponding increase in exercise prices, which is expected to enhance stock price stability and bolster investor confidence.
See More
Co-Diagnostics Secures Australian Patent for PCR Testing Platform
- Patent Protection Strengthened: Co-Diagnostics has been granted Australian Patent No. AU2022270084A1, marking the first patent for its novel Co-Dx PCR platform, which enhances the company's intellectual property in nucleic acid detection and analysis, thereby boosting its market competitiveness.
- Market Potential Enhanced: The patent specifically covers the design and operation of the Co-Dx PCR Pro™ instrument and test cups, aimed at facilitating high-quality PCR testing outside traditional laboratory settings to meet the growing market demand.
- Strategic Positioning: Following a record-breaking flu season in Australia, the patent grant provides strategic protection for Co-Dx's potential commercial partners to introduce or distribute the platform in the region, safeguarding its commercial potential.
- Technological Innovation: The Co-Dx PCR platform leverages patented Co-Primers® technology to deliver rapid, sensitive, and specific molecular diagnostics, promoting widespread applications in infectious disease testing and further solidifying the company's leadership in the molecular diagnostics field.
See More
Co-Diagnostics Secures Australian Patent for PCR Testing Platform
- Patent Protection Strengthened: Co-Diagnostics has been granted Australian Patent No. AU2022270084A1, marking the first patent for its new Co-Dx PCR platform, which enhances the company's intellectual property protection in molecular diagnostics and establishes a legal foundation for future commercial partnerships.
- Market Potential Enhanced: The patent covers the design and operation of the Co-Dx PCR Pro™ instrument and test cups, providing broad market protection, particularly in the context of Australia's record-breaking flu season, thereby safeguarding the commercial potential of the platform.
- Technological Innovation Advancing: The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy suitable for decentralized testing environments, leveraging the company's patented Co-Primers® technology to enable rapid and sensitive molecular diagnostics, addressing the growing market demand.
- Global Expansion Strategy: CEO Dwight Egan emphasized that the patent grant represents a significant milestone in securing global protection for the technology, supporting the company's mission to promote PCR testing worldwide, especially in light of the increasing demand for rapid testing post-pandemic.
See More
Co-Diagnostics Joins Advanced TB Diagnostics Workshop in Southeast Asia
- Collaborative Opportunity: Co-Diagnostics' joint venture, CoSara Diagnostics, has been invited to participate in the 2nd Advanced TB Diagnostics Course from December 15-19, 2025, in Chennai, India, aimed at enhancing tuberculosis detection capabilities in the Southeast Asian region, showcasing the company's influence in global health.
- Industry Engagement: Hosted by ICMR-NIRT and the McGill International TB Centre, the workshop gathers experts from organizations like WHO and the Gates Foundation, highlighting Co-Diagnostics' strategic importance in advancing tuberculosis detection technology.
- Technology Showcase: The event will feature technology pitches from industry innovators, presenting emerging diagnostic solutions, indicating Co-Diagnostics' leading position in tuberculosis detection and paving the way for future market opportunities.
- Policy Development: The workshop will explore evidence-based policy development and cost-effectiveness modeling, emphasizing Co-Diagnostics' potential contributions to public health policy and technology application, further solidifying its leadership in the molecular diagnostics market.
See More
Co-Diagnostics Strengthens Distributor Network in India with CoSara
- Distributor Network Expansion: CoSara Diagnostics has strengthened its distributor base in India, exceeding 40 distributors, and enhanced market penetration through participation in regional conferences.
- Product Promotion Opportunities: At two recent regional conferences, CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform, attracting new customers and solidifying existing relationships.
- Clinical Study Preparation: CoSara is preparing to assist in clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis test, demonstrating its active involvement in public health initiatives.
- Manufacturing Collaboration: CoSara will participate in the production of the PCR Pro™ instrument and MTB test cups, supporting the
See More
Co-Diagnostics Strengthens Distributor Network in India with CoSara, Expanding to Over 40 Distributors
- Distributor Network Expansion: CoSara Diagnostics is strengthening its distribution network in India by participating in two regional conferences, successfully attracting new customers and expanding its base of over 40 distributors, indicating positive progress in market penetration.
- Product Promotion Opportunities: At the conferences, CoSara introduced its SARAGENE® diagnostic products and the upcoming Co-Dx™ PCR platform, aiming to enhance brand visibility and lay the groundwork for future sales, further driving growth in the Indian market.
- Clinical Study Preparation: CoSara is preparing for clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) test, which not only helps enhance product market recognition but also strengthens its influence in public health.
- Manufacturing Collaboration: CoSara will participate in the manufacturing of the PCR Pro™ instrument and MTB test cups, supporting the
See More
Co-Diagnostics Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing
- Reverse Stock Split: Co-Diagnostics announced a 1-for-30 reverse stock split effective January 2, 2026, aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1.00, thereby mitigating delisting risks.
- Shareholder Approval: The reverse split was approved by shareholders at a special meeting on December 5, 2025, reflecting strong support for corporate governance and future growth, which enhances market confidence.
- Stock Trading Adjustment: Following the reverse split, Co-Diagnostics' stock will continue trading on Nasdaq under the new CUSIP number 189763 204, ensuring a smooth transition for investors into the adjusted trading environment.
- Equity Incentive Impact: The split will affect the number of stock options and warrants outstanding, with a corresponding increase in exercise prices, which is expected to enhance stock price stability and bolster investor confidence.
See More
Co-Diagnostics Secures Australian Patent for PCR Testing Platform
- Patent Protection Strengthened: Co-Diagnostics has been granted Australian Patent No. AU2022270084A1, marking the first patent for its novel Co-Dx PCR platform, which enhances the company's intellectual property in nucleic acid detection and analysis, thereby boosting its market competitiveness.
- Market Potential Enhanced: The patent specifically covers the design and operation of the Co-Dx PCR Pro™ instrument and test cups, aimed at facilitating high-quality PCR testing outside traditional laboratory settings to meet the growing market demand.
- Strategic Positioning: Following a record-breaking flu season in Australia, the patent grant provides strategic protection for Co-Dx's potential commercial partners to introduce or distribute the platform in the region, safeguarding its commercial potential.
- Technological Innovation: The Co-Dx PCR platform leverages patented Co-Primers® technology to deliver rapid, sensitive, and specific molecular diagnostics, promoting widespread applications in infectious disease testing and further solidifying the company's leadership in the molecular diagnostics field.
See More
Co-Diagnostics Secures Australian Patent for PCR Testing Platform
- Patent Protection Strengthened: Co-Diagnostics has been granted Australian Patent No. AU2022270084A1, marking the first patent for its new Co-Dx PCR platform, which enhances the company's intellectual property protection in molecular diagnostics and establishes a legal foundation for future commercial partnerships.
- Market Potential Enhanced: The patent covers the design and operation of the Co-Dx PCR Pro™ instrument and test cups, providing broad market protection, particularly in the context of Australia's record-breaking flu season, thereby safeguarding the commercial potential of the platform.
- Technological Innovation Advancing: The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy suitable for decentralized testing environments, leveraging the company's patented Co-Primers® technology to enable rapid and sensitive molecular diagnostics, addressing the growing market demand.
- Global Expansion Strategy: CEO Dwight Egan emphasized that the patent grant represents a significant milestone in securing global protection for the technology, supporting the company's mission to promote PCR testing worldwide, especially in light of the increasing demand for rapid testing post-pandemic.
See More
Co-Diagnostics Joins Advanced TB Diagnostics Workshop in Southeast Asia
- Collaborative Opportunity: Co-Diagnostics' joint venture, CoSara Diagnostics, has been invited to participate in the 2nd Advanced TB Diagnostics Course from December 15-19, 2025, in Chennai, India, aimed at enhancing tuberculosis detection capabilities in the Southeast Asian region, showcasing the company's influence in global health.
- Industry Engagement: Hosted by ICMR-NIRT and the McGill International TB Centre, the workshop gathers experts from organizations like WHO and the Gates Foundation, highlighting Co-Diagnostics' strategic importance in advancing tuberculosis detection technology.
- Technology Showcase: The event will feature technology pitches from industry innovators, presenting emerging diagnostic solutions, indicating Co-Diagnostics' leading position in tuberculosis detection and paving the way for future market opportunities.
- Policy Development: The workshop will explore evidence-based policy development and cost-effectiveness modeling, emphasizing Co-Diagnostics' potential contributions to public health policy and technology application, further solidifying its leadership in the molecular diagnostics market.
See More
